cefoperazone, cefotaxime, cefsulodin, sulbenicillin, and gentamicin. SM-1652 was relatively stable to hydrolysis with plasmid-mediated penicillinases and cephalosporinases produced by gram-negative bacteria.
Cephalosporin antibiotics are important chemotherapeutic agents because of their broad antibacterial spectra. However, the incidence of infections caused by bacteria resistant to older cephalosporins has increased recently. Therefore, it has been necessary to develop new cephalosporin antibiotics that have more potent antibacterial activities, broader antibacterial spectra and higher effectiveness against resistant bacteria. Therefore, several new cephalosporin derivatives, such as cefotaxime (1) and cefoperazone (4) , have been developed in the last few years. These new cephalosporins have higher stability to ,-lactamases, broader antibacterial spectra, and more potent antibacterial activities against gram-negative bacteria than those of older cephalosporins. However Strains. All of the clinical isolates were collected in 1978 at the Osaka National Hospital and some other hospitals in Kyoto, Japan. ,-Lactamase-producing strains were supplied by Gunma University, Maebashi, Japan.
Antibiotics. SM-1652 was prepared in the research laboratory of the Pharmaceuticals Division of Sumitomo Chemical Co. Ltd., Osaka, Japan. Cefoperazone and cefotaxime were also synthesized in our own research laboratory. The other antibiotics used were commercially available.
MIC determinations. Minimal inhibitory concentrations (MICs) were determined by a serial twofold agar dilution method with heart infusion agar (Nissui Seiyaku Co., Ltd., Tokyo). Tryptosoya broth (Nissui) was used for the preparation of seed suspensions.
Heart infusion agar and Trypotosoya broth were supplemented with 10%6 defibrinated rabbit blood for streptococci. The inoculum was grown overnight at 37°C ( The activities of SM-1652, cefazolin, cefoperazone (4), and cefotaxime (1) against Enterobacteriaceae are shown in Table 2 . Against E. coli, Salmonella spp., Klebsiella pneumoniae, and Proteus mirabilis, SM-1652 was as active as or slightly less active than cefazolin. SM-1652, however, showed 10-to 60-fold higher activity than cefazolin against Proteus vulgaris, Morganella morganii, Enterobacter cloacae, and Serratia spp. The activity of cefoperazone against Enterobacteriaceae was superior to those of SM-1652 and cefazolin, but less active than cefotaxime against most species. Finally, SM-1652 did not exceed cefoperazone and cefotaxime in potency but did exceed cefazolin in potency and broadness of activity against Enterobacteriaceae.
The high activity of SM-1652 against Pseudo- Providencia rettgeri (11) Citrobacterfreundii ( Stability to ,-1actmase. SM-1652 was relatively stable to P-lactamases produced by various species (Table 5) . SM-1652 was much more stable than cephaloridine and cefazolin and almost as stable as cefoperazone and cefotaxime to cephalosporinases produced by Escherichia coli GN5482, M. morganii GN926, Citrobacter freundii GN346, and Pseudomonas aeruginosa GN918 (14) . SM-1652 also showed a high stability to penicillinase type IV (carbenicillin-hydrolyzing enzyme [7, 11] ) and Staphylococcus aure- [5] ) and penicillinases types I (TEM type [12] ), II (oxacillin-hydrolyzing enzyme [16] ), and III (oxacillin-hydrolyzing enzyme [15] ). The stability of SM-1652 to ,B-lactamase was almost the same as that of cefoperazone. DISCUSSION SM-1652 is a new parenteral cephalosporin derivative with a broad spectrum of antibacterial activity. This antibiotic has been reported to have potent in vitro and in vivo antibacterial activities against gram-positive and -negative bacteria (2) . This paper showed that SM-1652 exceeded cefazolin in potency and broadness of antibacterial spectrum but did not exceed cefoperazone and cefotaxime in potency against Enterobacteriaceae. An interesting feature of the antibacterial activity of SM-1652 is its high activity against Pseudomonadaceae. At a concentration of 12.5 ,ug/ml, SM-1652 inhibited 87% ofPseudomonas aeruginosa clinical isolates. It was as active as cefsulodin, the only cephalosporin with a selective activity against Pseudomonas aeruginosa. SM-1652 was also effective against cefsulodin-and gentamicin-resistant Pseudomonas aeruginosa, but its activities were 3-to 20-fold less than those against clinical isolates of this species. These diminished activities of SM-1652 may reflect the fact that 48% of the cefsulodinresistant Pseudomonas aeruginosa strains and 40% of the gentamicin-resistant Pseudomonas aeruginosa strains showed resistance to gentamicin and cefsulodin, respectively. SM-1652 was more effective than cefoperazone, cefotaxime, cefsulodin, sulbenicillin, and gentamicin against Pseudomonas maltophilia and Pseudomonas cepacia, the two Pseudomonadaceae species other than Pseudomonas aeruginosa which are important pathogens in opportunistic infections and are in general resistant to the aminoglycosides. SM-1652 was relatively stable to P-lactamases produced by various species.
A preliminary report of a study done in humans indicates that the plasma half-lives of SM-1652 in intravenous doses of 0.5 and 1 g are 3.9 and 5.1 h, respectively (K. Nakagawa, M. Koyama, N. Nakatsuru, K. Yoshinaga, H. Matsui, C. Ikeda, K. Yano, and T. Noguchi, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 20th, New Orleans, La., abstr. no. 149, 1980). These half-lives of SM-1652 are more prolonged than any others so far reported on cephalosporin derivatives except ceftriaxone (Ro 13-9904) (K. Stoeckel, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother.
21st, Chicago, Ill., abstr. no. 387, 1981). The potent antipseudomonal activity and the broad spectrum of SM-1652, coupled with its good pharmacokinetics in humans, suggests that it should be an effective therapeutic agent, particularly against Pseudomonas aeruginosa infections.
